How Does Mounjaro Work? The Science Behind Tirzepatide

The Short Answer

Mounjaro (tirzepatide) causes weight loss by activating two gut-derived hormone receptors — GIP and GLP-1 — simultaneously. This dual mechanism suppresses appetite more powerfully than any previously available weight loss injection, slows the passage of food through the stomach, reduces total calorie intake, and improves insulin sensitivity. The result, in clinical trials, is an average weight loss of nearly 21% of body weight — results previously achievable only through bariatric surgery.

But to understand why this dual activation is so effective, it helps to understand what each hormone does on its own.

What Is GLP-1 and What Does It Do?

GLP-1 — glucagon-like peptide-1 — is a hormone produced in the small intestine in response to eating. It has several important effects:

• Signals fullness to the brain — GLP-1 binds to receptors in the hypothalamus (the appetite regulation centre), suppressing hunger and reducing food intake
• Stimulates insulin secretion — in a glucose-dependent manner, helping to manage blood sugar after meals
• Inhibits glucagon — reducing the liver’s glucose output and further stabilising blood sugar
• Slows gastric emptying — food moves more slowly from the stomach to the small intestine, prolonging the feeling of fullness

GLP-1 receptor agonists such as liraglutide (Saxenda) and semaglutide (Wegovy) mimic this hormone at pharmacological doses, producing meaningful but ultimately limited weight loss through this single pathway.

What Is GIP — and Why Does It Matter?

GIP — glucose-dependent insulinotropic polypeptide — is a second gut hormone released after eating. It was initially thought to work primarily on the pancreas, enhancing insulin secretion. For years, GIP was not considered a promising target for obesity treatment — in fact, some research suggested activating GIP receptors in isolation could promote fat storage.

The breakthrough insight behind tirzepatide was that activating GIP and GLP-1 receptors simultaneously produces a synergistic effect that neither hormone achieves alone. When both pathways are engaged together:

• GIP appears to enhance and amplify the appetite-suppressing effects of GLP-1 in the brain
• GIP activation in fat tissue may reduce fat storage rather than promote it — the opposite of what occurs when GIP acts alone
• The combined insulin response is more robust and glucose-stabilising than GLP-1 alone

This synergy is the fundamental reason Mounjaro outperforms GLP-1 agonists alone.

The Dual GIP + GLP-1 Advantage

The dual mechanism produces benefits across multiple physiological systems:

How Mounjaro Suppresses Appetite in Practice

What does dual GIP and GLP-1 activation actually feel like for someone taking Mounjaro? Clinical trial participants and patients report a consistent set of subjective changes:

• Meals feel satisfying with significantly smaller portions than before
• Hunger between meals is noticeably reduced — or absent entirely in many users at higher doses
• Food “noise” — the persistent mental preoccupation with food that many overweight people experience — diminishes or disappears
• Cravings for ultra-processed, high-calorie foods often reduce
• Eating to a comfortable fullness requires far less food than previously

This is not willpower. These are physiological changes driven by altered hormone signalling — which is precisely why Mounjaro is effective even for people who have repeatedly struggled to maintain calorie restriction through lifestyle changes alone.

Effects on Metabolism and Blood Sugar

Beyond appetite suppression, Mounjaro produces meaningful metabolic benefits that compound its weight loss effects:

• Improved insulin sensitivity — reduces insulin resistance, making the body more efficient at processing glucose
• Reduced fasting blood glucose — particularly significant for people with type 2 diabetes or pre-diabetes
• Lower blood pressure — observed in SURMOUNT trial participants independent of the weight loss effect
• Improved lipid profile — reductions in LDL cholesterol and triglycerides, improvements in HDL cholesterol
• Reduced liver fat — tirzepatide has shown promising results for non-alcoholic fatty liver disease

These metabolic benefits mean Mounjaro addresses not just weight, but many of the key health risks associated with obesity.

How Quickly Does Mounjaro Work?

What Happens When You Stop Mounjaro?

This is one of the most important questions for anyone considering Mounjaro. The SURMOUNT-4 trial directly addressed it: participants who achieved significant weight loss on Mounjaro and then switched to placebo regained approximately two-thirds of their lost weight within 52 weeks.

This is not a failure of the drug — it reflects the chronic nature of obesity as a condition. When Mounjaro is stopped, appetite returns to pre-treatment baseline as the drug clears the system. Without the hormonal appetite suppression, and unless profound lifestyle changes have been embedded, weight typically returns.